Form 4 for EW Edwards Lifesciences
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-07 · accession 0001225208-22-006817 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-10 | 2022-05-10 | EW | Wood Larry L | CVP, TAVR | S - Sale+OE | $96.13 | -7,242 | 206.1K | -3% | -$696.2K |
| DM | 2022-05-10 | 2022-05-08+ | EW | Wood Larry L | CVP, TAVR | M - OptEx | $12.98 | +20.5K | 214.1K | +11% | +$266.1K |
| DM | 2022-05-10 | 2022-05-07+ | EW | Wood Larry L | CVP, TAVR | F - Tax | $100.52 | -8,686 | 200.8K | -4% | -$873.1K |
| DM | 2022-05-10 | 2022-05-08+ | EW | Wood Larry L | CVP, TAVR | M - OptEx | $0.00 | -20.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-10 | S | D | 2,674 | $95.71 | 210,637.03 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $95.16 to $96.14. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-05-10 | S | D | 4,568 | $96.38 | 206,069.03 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $96.18 to $96.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-05-10 | M | A | 7,242 | $36.75 | 213,311.03 | D | — | — | |
| 4 | Common | Common Stock | 2022-05-08 | F | D | 8,007 | $100.52 | 206,069.03 | D | — | — | |
| 5 | Common | Common Stock | 2022-05-08 | M | A | 13,256 | $0.00 | 214,076.03 | D | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 6 | Common | Common Stock | 2022-05-07 | F | D | 679 | $100.52 | 200,820.03 | D | — | — | |
| 7 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-10 | M | D | 7,242 | $0.00 | 50,688 | D | $36.75 · 2018-05-11 to 2024-05-10 | 7,242 Common Stock | |
| 8 | Derivative | Performance Rights | 2022-05-08 | M | D | 13,256 | $0.00 | 0 | D | — · 2022-05-08 to 2026-05-07 | 13,256 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |